Cargando…
A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models
Previous studies show that cyclophilins contribute to many pathologic processes, and cyclophilin inhibitors demonstrate therapeutic activities in many experimental models. However, no drug with cyclophilin inhibition as the primary mode of action has advanced completely through clinical development...
Autores principales: | Kuo, Joseph, Bobardt, Michael, Chatterji, Udayan, Mayo, Patrick R., Trepanier, Daniel J., Foster, Robert T., Gallay, Philippe, Ure, Daren R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Pharmacology and Experimental Therapeutics
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815936/ https://www.ncbi.nlm.nih.gov/pubmed/31406003 http://dx.doi.org/10.1124/jpet.119.261099 |
Ejemplares similares
-
The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice
por: Gallay, Philippe, et al.
Publicado: (2019) -
The cyclophilin inhibitor CRV431 prevents both cyclophilin A-HBx complex formation and HBV replication
por: Foster, R.T., et al.
Publicado: (2017) -
The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
por: Gallay, Philippe A., et al.
Publicado: (2015) -
Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice
por: Bobardt, Michael, et al.
Publicado: (2020) -
In Vitro Phase I Metabolism of CRV431, a Novel Oral Drug Candidate for Chronic Hepatitis B
por: Trepanier, Daniel J., et al.
Publicado: (2017)